VIRTUS CLINICAL TRIAL

12-Month Data¹
Pivotal Cohort 12-Month Primary Safety and Efficacy Results of the VICI Venous Stent™ System

OBJECTIVE:
Assess safety & effectiveness in achieving patency of target venous lesion through 12 months post stent placement, in patients with obstruction of the iliofemoral venous outflow tract

TRIAL DESIGN:
Prospective, multi-center (22 sites in the US and Europe) single arm, non-randomized

BASELINE CHARACTERISTICS:

<table>
<thead>
<tr>
<th>Patient Demographics</th>
<th>n = 170 subjects</th>
<th>Clinical Assessment</th>
<th>n = 170 subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Years)</td>
<td>54.4±16.2</td>
<td>Chronic PostThrombotic</td>
<td>75.0%</td>
</tr>
<tr>
<td>Male/Female</td>
<td>43.5%/56.5%</td>
<td>CEAP Clinical Severity C &amp; C</td>
<td>25.3%</td>
</tr>
<tr>
<td>Thromboembolic Disease</td>
<td>76.5%</td>
<td>VCSS ≥ 8, Severe</td>
<td>65.8%</td>
</tr>
<tr>
<td>History of Smoking</td>
<td>36.5%</td>
<td>Lesion Length</td>
<td>111.3±65.8 (range 10-260 mm)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>40.0%</td>
<td>Total Occlusions</td>
<td>31.2%</td>
</tr>
<tr>
<td>Coagulation Disorder</td>
<td>13.5%</td>
<td>% Involving entire iliofemoral segment</td>
<td>31.8%</td>
</tr>
<tr>
<td>Peripheral Vascular Disease</td>
<td>17.1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

EFFICACY RESULTS:
Definition:
Primary patency rate at 12 months post-intervention
• Freedom from occlusion by thrombosis
• Freedom from surgical or endovascular intervention on target vessel which are found to have re-stenosis or stent occlusion to maintain patency
• Freedom from in-stent stenosis more than 50% by venogram

Primary endpoint was met²:
Primary patency rate exceeded the performance goal of 72.1% (p<0.0001)³⁴

12-Month Primary Patency Rate³

Etiology

Non-thrombotic 25%
Post-thrombotic 75%

100% 84.0% 72.1%
90% 80% 70%
80% 70% 60%
70% 60% 50%
60% 50% 40%
50% 40% 30%
40% 30% 20%
30% 20% 10%
20% 10% 0%

VICI Endpoint
Performance Goal

p=0.0001
Safety Results:
98.8% freedom from MAEs through 30 days

Primary endpoint was met:
Safety rate exceeded the performance goal of 94%

Patient Outcomes:
- VIRTUS demonstrated a clinically meaningful 4.4 decrease in the VCSS score from baseline out to 12 months.
- Vici shifted patients with a severe VCSS score from almost 66% down to 27%, and increased the patients in the mild VCSS score 4-fold.

Conclusions:
- VIRTUS primary safety and effectiveness endpoints successfully met:
  - 84% 12-month primary patency
  - 98.8% freedom from MAE through 30 days
- Patient sample with challenging characteristics:
  - 75% of patients with chronic PTS
  - 65.8% VCSS ≥ 8, severe
  - 25% of patients with CEAP Clinical Severity C5 and C6
  - 31% with total occlusions
  - 32% had involvement of the entire iliofemoral segment

1. Presented at LINC 2019 by Mahmood K. Razavi, MD, VIRTUS clinical trial principle investigator
2. The objective performance goal for the primary safety and efficacy endpoints were derived from contemporary literature.
3. For the primary endpoint, patients who did not have venography performed at 12 months had their result imputed by random selection from subjects with a venogram result who had the same etiology and the same DUS outcome (if available).
4. Primary effectiveness analysis based on the combined result from 15 imputations; t-statistic 4.0; p<0.0001
5. Lower confidence limit of 95.8% exceeded the performance goal of 94%